About this Medicine article
Improved Cancer-specific Free Survival and Overall Free Survival in Contemporary Metastatic Prostate Cancer Patients: a Population-based Study by Marco Bandini; Raisa S. Pompe; Michele Marchioni; Emanuele Zaffuto; Giorgio Gandaglia; Nicola Fossati; Luca Cindolo; Francesco Montorsi; Alberto Briganti; Fred Saad; Pierre I. Karakiewicz is a Medicine article available to read on EtoBox.
## Objectives: Over the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-t, abiraterone and enzalutamide have improved overall survival (os) in metastatic prostate cancer (mpca) patients. however, to date the os benefit was not demonstrated in population-based analysis. ## Methods: Between 2004 and 2014, 19,047 men with de novo mpca were identified within the surveillance epidemiology and end results database. median year of diagnosis resulted in two groups: historical (2004-2008) and contemporary (2009-2014). due to potentially important differences according to year of diagnosis, we relied on propensity score matching. propensity-score-matched kaplan-meier analyses and cox regression models (crms) tested cancer-specific mortality (csm) free survival and overall mortality (om) free survival according to treatment period. ## Results: The propensity-score-matched cohort consisted of 8596 patients with mpca. of those, 4298 (50.0%) were historical (2004-2008) and 4298 (50.0%) were contemporary (2009-2014). csm free survival rates and om free survival rate were 32 versus 36 months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively, historical
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Marco Bandini; Raisa S. Pompe; Michele Marchioni; Emanuele Zaffuto; Giorgio Gandaglia; Nicola Fossati; Luca Cindolo; Francesco Montorsi; Alberto Briganti; Fred Saad; Pierre I. Karakiewicz
- Publisher
- Springer Science and Business Media LLC
- Published
- 2017
- Language
- EN
- Field
- Medicine (Health Sciences)